Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.

Journal of medical virology - 1 Oct 2024

Chaix Marie-Laure, Terracol Laura, Nere Marie-Laure, Stefic Karl, Lascoux-Combe Caroline, Manda Victoria, Sellier Pierre, Maylin Sarah, Molina Jean-Michel, Liegeon Geoffroy, Delaugerre Constance, Salmona Maud

Abstract excerpt

Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to France

Share to HIV Antibodies

Share to HIV Infections

Share to Organophosphates

Share to Piperazines

Source

Identifiers

PMID: 39363782
DOI: 10.1002/jmv.29948

Genes

CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.PMID 39363782Read ↗

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017-2023.Semantic proximity Read ↗

Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios.Semantic proximity Read ↗

Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.Semantic proximity Read ↗

Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).Semantic proximity Read ↗

Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.Semantic proximity Read ↗

Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021.Semantic proximity Read ↗

Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation.Semantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI ResistanceSemantic proximity Read ↗

National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.